Decisions in health technology assessment: should we speak with one voice?

Clicks: 434
ID: 85045
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Abstract Decisions regarding the regulation of individual medicines differ from country to country. In the case of Relenza, Mulinari and Davis (Health Res Policy Syst 15:93, 2017) have suggested that these inconsistencies are primarily due to processes, statistical methodologies and technical capacity varying between regulatory agencies. They go on to name specific individuals involved in the evaluation of this anti-influenza medicine and imply that differences in the judgements of these individuals has affected public policy concerning the market access of this medicine. This Commentary argues that what may appear as inconsistent decision-making may in fact be due to differences in the applicability of the evidence base to the local population and health system for which each regulator has responsibility. If health technology assessors are providing nuanced judgements on the effectiveness of a medicine for the local population, differences in regulation and reimbursement decisions are to be expected.
Reference Key
merlin2018decisionshealth Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Merlin, Tracy;
Journal health research policy and systems
Year 2018
DOI
DOI not found
URL
http://link.springer.com/article/10.1186/s12961-018-0385-y
Keywords
chemistry Biology (General) Medicine Science psychology neoplasms. tumors. oncology. including cancer and carcinogens public aspects of medicine plant culture genetics

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.